Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients
Status:
Completed
Trial end date:
1994-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness of pyrimethamine (given with leucovorin calcium versus placebo
(an inactive substance) for the primary prophylaxis (prevention) of cerebral toxoplasmosis in
HIV-infected patients.
Cerebral toxoplasmosis is one of the most frequently encountered opportunistic infections in
the course of AIDS. The mortality (death) rate is estimated to be greater than 50 percent.
Pyrimethamine is a drug that appears promising for the primary prevention of cerebral
toxoplasmosis in HIV-infected patients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)